Roivant Sciences Ltd.
For the period ended Jun 30, 2025. Filed Aug 11, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 11, 2025
ROIV$38.88+6.2%Stored close · as of Nov 6, 2026
Contents
Condensed Consolidated Balance Sheets as of June 30, 2025 and March 31, 2025
Balance Sheets
(unaudited, in thousands, except share and per share amounts)
| June 30, 2025 | March 31, 2025 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $1,238,459 | $2,715,411 |
| Marketable securities (includes $1,803,035 of available-for-sale marketable securities held at fair value as of June 30, 2025) | 3,264,692 | 2,171,480 |
| Other current assets | 112,600 | 113,173 |
| Total current assets | 4,615,751 | 5,000,064 |
| Property and equipment, net | 14,865 | 12,056 |
| Operating lease right-of-use assets | 87,078 | 89,021 |
| Investments measured at fair value | 283,814 | 302,939 |
| Other assets | 31,094 | 32,860 |
| Total assets | $5,032,602 | $5,436,940 |
| Liabilities and Shareholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $11,550 | $23,691 |
| Accrued expenses | 88,728 | 114,294 |
| Operating lease liabilities | 9,402 | 9,842 |
| Other current liabilities | 4,186 | 1,584 |
| Total current liabilities | 113,866 | 149,411 |
| Liability instruments measured at fair value | 12,310 | 9,981 |
| Operating lease liabilities, noncurrent | 90,292 | 90,328 |
| Other liabilities | 228 | 22 |
| Total liabilities | 216,696 | 249,742 |
| Commitments and contingencies (Note 11) | ||
| Shareholders’ equity: | ||
| Common shares, par value $0.0000000341740141 per share, 7,000,000,000 shares authorized and 682,229,832 and 695,938,323 shares issued and outstanding at June 30, 2025 and March 31, 2025, respectively | — | — |
| Additional paid-in capital | 4,644,085 | 4,562,107 |
| (Accumulated deficit) / retained earnings | (315,588) | 116,060 |
| Accumulated other comprehensive income | 17,137 | 9,438 |
| Shareholders’ equity attributable to Roivant Sciences Ltd. | 4,345,634 | 4,687,605 |
| Noncontrolling interests | 470,272 | 499,593 |
| Total shareholders’ equity | 4,815,906 | 5,187,198 |
| Total liabilities and shareholders’ equity | $5,032,602 | $5,436,940 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.